Lisata Therapeutics Inc. (0HS8)
LSE 
Summary
0HS8 Chart
Anthropic is compounding, OpenAI is flatlining, and the betting markets have noticed
Two of the biggest listings in market history are queued up for the back end of this year, and punters are already pricing the run-in. Polymarket has opened...
Lisata Therapeutics moves forward with legal action following Kuva merger termination
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said on Tuesday it has taken decisive action following the termination of its merger agreement with Kuva Labs and its subsidiary Kuva Acquisition Corp, filing suit to protect stockholder interests and moving swiftly to strengthen its financial position. The clinical-stage pharmaceutical company, which develops therapies for advanced solid tumors, filed the lawsuit in the Delaware Court of Chancery, alleging Kuva breached the merger agreement dated March 6, 2026.
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has agreed to be acquired by privately held Kuva Labs Inc. for $4 per share in cash, plus a contingent value right worth up to an additional $3.00 per share tied to drug development milestones.
Lisata Therapeutics Inc. (0HS8) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Lisata Therapeutics Inc. ever had a stock split?
Lisata Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | David J. Mazzo CEO | LSE Exchange | US1280583022 ISIN |
| US Country | 21 Employees | - Last Dividend | 15 Sep 2022 Last Split | 1 Mar 1999 IPO Date |
Overview
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company dedicated to developing innovative therapies for the treatment of solid tumors and various diseases. Founded in 1980, the company has been at the forefront of research and development in oncology and other critical areas of medicine. Headquartered in Basking Ridge, New Jersey, Lisata Therapeutics aims to deliver breakthrough treatments that can significantly improve patient outcomes. With a focus on identifying and advancing promising drug candidates, the company is committed to addressing some of the most challenging medical conditions faced today.
Products and Services
- LSTA1
This product candidate is currently in Phase 2a and 2b clinical studies for the treatment of solid tumors. It shows particular promise in the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) when used in combination with various anti-cancer regimens. LSTA1 represents Lisata Therapeutics' dedication to combating one of the most aggressive and hard-to-treat cancers.
- XOWNA
XOWNA is another innovative treatment under development, currently undergoing a Phase IIa clinical trial. It is designed for the treatment of coronary microvascular dysfunction, a condition that affects the small vessels supplying blood to the heart muscle. This represents a significant advancement in addressing a key area of unmet medical need in cardiovascular disease.
- CD34+ Cell Therapy
Targeting chronic kidney disease, this CD34+ cell therapy is among Lisata Therapeutics' novel approaches to treating chronic conditions with high unmet clinical needs. By leveraging the potential of CD34+ cells, this therapy aims to offer new hope to patients suffering from chronic kidney disease, showcasing the company's commitment to innovating in areas where traditional treatments have fallen short.
